title: Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbits.
abstract: A recent study (Fernandez et al., Thromb. Haemostas. 1987; 57: 286-93) demonstrated that when rabbits were injected with the minimum weight of a variety of glycosaminoglycans required to inhibit tissue factor-induced thrombus formation by approximately 80%, exogenous thrombin was inactivated approximately twice as fast in the post-treatment plasmas as the pre-treatment plasmas. In this study, we investigated the relationship between inhibition of thrombus formation and the extent of thrombin inhibition ex vivo. We also investigated the relationship between inhibition of thrombus formation and inhibition of prothrombin activation ex vivo. Four sulfated polysaccharides (SPS) which influence coagulation in a variety of ways were used in this study. Unfractionated heparin and the fraction of heparin with high affinity to antithrombin III potentiate the antiproteinase activity of antithrombin III. Pentosan polysulfate potentiates the activity of heparin cofactor II. At less than 10 micrograms/ml of plasma, all three SPS also inhibit intrinsic prothrombin activation. The fourth agent, dermatan sulfate, potentiates the activity of heparin cofactor II but fails to inhibit intrinsic prothrombin activation even at concentrations which exceed 60 micrograms/ml of plasma. Inhibition of thrombus formation by each sulfated polysaccharides was linearly related to the extent of thrombin inhibition achieved ex vivo. These observations confirm the utility of catalysis of thrombin inhibition as an index for assessing antithrombotic potential of glycosaminoglycans and other sulfated polysaccharides in rabbits. With the exception of pentosan polysulfate, there was no clear relationship between inhibition of thrombus formation and inhibition of prothrombin activation ex vivo.
authors.affiliation: McMaster University, Hamilton, Ont., Canada.
authors.forename: F A
authors.initials: FA
authors.lastname: Ofosu
authors.forename: F
authors.initials: F
authors.lastname: Fernandez
authors.forename: N
authors.initials: N
authors.lastname: Anvari
authors.forename: C
authors.initials: C
authors.lastname: Caranobe
authors.forename: F
authors.initials: F
authors.lastname: Dol
authors.forename: Y
authors.initials: Y
authors.lastname: Cadroy
authors.forename: M
authors.initials: M
authors.lastname: Petitou
authors.forename: J
authors.initials: J
authors.lastname: Mardiguian
authors.forename: P
authors.initials: P
authors.lastname: Sié
authors.forename: B
authors.initials: B
authors.lastname: Boneu
mesh_terms: D000818:Animals; D015951:Factor Xa; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D010314:Partial Thromboplastin Time; D011134:Polysaccharides / Q000494:pharmacology*; D011817:Rabbits; D015842:Serine Proteinase Inhibitors; D013917:Thrombin / Q000037:antagonists & inhibitors; D013918:Thrombin Time
chemical_list: D005343:Fibrinolytic Agents; D011134:Polysaccharides; D015842:Serine Proteinase Inhibitors; D013917:Thrombin; D015951:Factor Xa